OBIO — Orchestra Biomed Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $104.98m
- $52.46m
- $2.64m
Annual cashflow statement for Orchestra Biomed Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 8-K | 8-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -21.4 | -23 | -33.6 | -49.1 | -61 |
| Depreciation | |||||
| Non-Cash Items | 3.22 | 0.774 | 4.55 | 6.01 | 10.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -8.19 | 2.63 | -0.451 | -3.31 | -0.765 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -26.2 | -19.4 | -29.3 | -46.1 | -50.6 |
| Capital Expenditures | -0.539 | -0.274 | -0.591 | -0.078 | -0.891 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 27.5 | 13.3 | -63.5 | 10.8 | 14 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 27 | 13 | -64.1 | 10.7 | 13.1 |
| Financing Cash Flow Items | — | 0 | -10.3 | 56.8 | -1.1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 10 | -3.99 | 103 | 46.2 | 29.2 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 10.8 | -10.4 | 9.85 | 10.8 | -8.3 |